Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Pharmacokinetic profile for EnaV in dose-escalation phase. Plasma/serum concentrations of (A) conjugated EnaV and (B) MMAE at 3Q4W. Dots indicate observed data; lines indicate mean data. EnaV, enapotamab vedotin; LLOQ, lower limit of quantitation; MMAE, monomethyl auristatin E</p>
Gorde:
| Egile nagusia: | |
|---|---|
| Beste egile batzuk: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Argitaratua: |
2025
|
| Gaiak: | |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| Gaia: | <p>Pharmacokinetic profile for EnaV in dose-escalation phase. Plasma/serum concentrations of (A) conjugated EnaV and (B) MMAE at 3Q4W. Dots indicate observed data; lines indicate mean data. EnaV, enapotamab vedotin; LLOQ, lower limit of quantitation; MMAE, monomethyl auristatin E</p> |
|---|